TiumBio
TiumBio is a South Korea-based biotechnology company running 2 late-stage cancer trials of TU2218 in biliary tract cancer, head and neck squamous cell carcinoma and colorectal cancer.
Overview
TiumBio, based in Seongnam, South Korea, is a biotechnology company. TiumBio develops treatments for rare and intractable diseases, including immunotherapies and biologics for cancer, hemophilia and endometriosis. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing TU2218 in biliary tract cancer, head and neck squamous cell carcinoma and colorectal cancer. The largest, NCT05204862 (Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumours), plans to enrol 240 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyVyriad
Shares Head and neck squamous cell carcinoma, Colorectal cancer and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyQBiotics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Biliary tract cancer (cholangiocarcinoma), Colorectal cancer and the tag ctgov-sponsor.
- CompanyHangzhou Hanx Biopharmaceuticals
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.
- CompanySTCube
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyAP Biosciences
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.